shopping cart Your cart is empty
  • Home
  • Biotechnology
  • Oncology Based Molecular Diagnostics Market By Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Can...

Oncology Based Molecular Diagnostics Market By Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Kidney Cancer), By Product (Instruments, Reagents), By Test Location (Clinics And Other Establishments, Point Of Care), By Technology (PCR, Transcription Mediated Amplification, Situ Hybridization, Sequencing, Isothermal Nucleic Acid Amplification Technology, Chips And Microarrays), Industry Size, Growth, Share And Forecast To 2022

Published By: Brisk Insights | Published On: May 9, 2016

Key Findings


The global oncology molecular diagnostics market has contributed $1139.5 million in 2014 and it is expected to grow around $3391 million at the CAGR of 15% during 2015-2022. The major factors that drives the global oncology molecular diagnostics market are increasing demand for molecular diagnostic devices due to the increasing number of cancer patients all over the world. Huge investment in diagnostics technological devices by various economies is boosting the global oncology molecular diagnostics market. The oncology molecular diagnostics market is expected to grow at higher rate in future due to increasing geriatric population base and increasing demand for treatment of cancer, such as breast cancer, lung cancer etc. Although there are many factors which drives the market but still there are certain challenges which are faced by the market such as high cost of treatments, unavailability of adequate resources and lack of technical expertise.


Market Segment Insight


The market is majorly segmented on the basis of types such as breast cancer, prostate cancer, colorectal cancer, cervical cancer, liver cancer, lung cancer, blood cancer, kidney cancer etc. On the basis of products the market is segmented into instruments, reagents, others etc. On the basis of test location it is segmented into clinics & other establishments and point of care. On the basis of technology the market is segmented into PCR, situ hybridization, isothermal nucleic acid amplification technology, chips and microarrays, sequencing, transcription mediated amplification and others. Among all types, breast cancer had the highest market share in 2014, contributing a sum of $170 million. On the basis of product, reagents dominated the overall market by 55% share in 2014.


Regional Insight


On the basis of region the market is segmented into North America, Europe, APAC and RoW. North America holds the largest market share and it is the fastest growing region followed by Asia Pacific, Europe and RoW. Whereas Asia is expected to be the fastest growing region for global oncology molecular diagnostics marketin next 6 to 7 years due to rising geriatric population and increasing awareness level of consumers regarding health issues. North America is expected to grow significantly due to rising healthcare infrastructure and increasing disposable income.


Competitive Insights


Some of the major market players are Abbott laboratories, Bayer healthcare, Bection dickinson, Cepheid, Dako, Danaher corporation, Gen probe (hologic), Qiagen n.v., Siemens healthcare etc. Acquisitions, expansions and mergers are the key strategies adopted by the market players to sustain in the market.

CHAP 1. METHODOLOGY & SCOPE 15
1.1. RESEARCH METHODOLOGY 15
1.2. RESEARCH SCOPE & ASSUMPTIONS 15
1.3. LIST OF DATA SOURCES 15


CHAP 2. EXECUTIVE SUMMARY 16
2.1. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET SUMMARY & KEY BUYING CRITERIA 16
2.2. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET OUTLOOK 16
2.3. MARKET SEGMENTATION ANALYSIS 16
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 16
2.5. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET VALUE CHAIN ANALYSIS 16
2.6. VENDOR LANDSCAPE 16


CHAP 3. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET 17
3.1. MARKET DRIVER ANALYSIS 17
3.1.1. INCREASING NUMBER OF CANCER PATIENTS 17
3.1.2. RISING DEMAND FOR INTENSIVE DIAGNOSTIC PROCEDURES 17
3.2. MARKET RESTRAINT ANALYSIS 17
3.2.1. RISING PRICES OF MOLECULAR DIAGNOSTICS TESTS 17
3.3. KEY OPPORTUNITIES 17
3.3.1. INCREASING TECHNOLOGICAL ADVANCEMENTS 17
3.3.2. UNTAPPED MARKET 17
3.4. CHALLENGES 17
3.4.1. UNDESIRABLE REGULATORY FRAMEWORK 17
3.4.2. LACK OF TECHNICAL EXPERTISE 17


CHAP 4. INDUSTRY ANALYSIS 18
4.1. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET– PORTER’S FIVE FORCE MODEL 18
4.2. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET– PESTEL ANALYSIS 18
4.3. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET– GAP ANALYSIS 18


CHAP 5. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY TYPE 2012-2022 ($ BILLION) 19
5.1. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BYBREAST CANCER 2012-2022 ($ BILLION) 19
5.2. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY PROSTATE CANCER 2012-2022 ($ BILLION) 19
5.3. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY COLORECTAL CANCER2012-2022 ($ BILLION) 19
5.4. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY CERVICAL CANCER 2012-2022 ($ BILLION) 19
5.5. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY LIVER CANCER 2012-2022 ($ BILLION) 19
5.6. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY LUNG CANCER 2012-2022 ($ BILLION) 19
5.7. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY BLOOD CANCER 2012-2022 ($ BILLION) 19
5.8. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY KIDNEY CANCER 2012-2022 ($ BILLION) 19
5.9. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY O THER CANCER 2012-2022 ($ BILLION) 19


CHAP 6. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY PRODUCT 2012-2022 ($ BILLION) 20
6.1. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY INSTRUMENTS 2012-2022 ($ BILLION) 20
6.2. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY REAGENTS 2012-2022 ($ BILLION) 20
6.3. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY OTHERS 2012-2022 ($ BILLION) 20


CHAP 7. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY TEST LOCATION 2012-2022 ($ BILLION) 21
7.1. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY CLINICS AND OTHER ESTABLISHMENTS 2012-2022 ($ BILLION) 21
7.2. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY POINT OF CARE 2012-2022 ($ BILLION) 21


CHAP 8. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2012-2022 ($ BILLION) 22
8.1. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY PCR 2012-2022 ($ BILLION) 22
8.1.1. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY MULTIPLEX 2012-2022 ($ BILLION) 22
8.1.2. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY MULTIPLEX PCR 2012-2022 ($ BILLION) 22
8.1.3. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY OTHERS 2012-2022 ($ BILLION) 22
8.2. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY TRANSCRIPTION MEDIATED AMPLIFICATION 2012-2022 ($ BILLION) 22
8.3. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY SITU HYBRIDIZATION2012-2022 ($ BILLION) 22
8.4. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY SEQUENCING 2012-2022 ($ BILLION) 22
8.5. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 2012-2022 ($ BILLION) 22
8.6. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY CHIPS AND MICROARRAYS 2012-2022 ($ BILLION) 22


CHAP 9. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET REGIONAL OUTLOOK 2012-2022 ($ BILLION) 23
9.1. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY REGION 2012-2022 ($ BILLION) 23
9.2. NORTH AMERICA 23
9.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
9.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 23
9.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
9.2.3.1. U.S. 23
9.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
9.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
9.2.3.2. CANADA 23
9.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
9.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
9.2.3.3. MEXICO 23
9.2.3.3.1. MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
9.2.3.3.2. MEXICO MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
9.3. EUROPE 24
9.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
9.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 24
9.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
9.3.3.1. GERMANY 24
9.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
9.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
9.3.3.2. UK 24
9.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
9.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
9.3.3.3. FRANCE 24
9.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
9.3.3.3.3. SPAIN 25
9.3.3.3.4. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.3.3.3.5. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
9.3.3.3.6. ITALY 25
9.3.3.3.7. ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.3.3.3.8. ITALY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
9.3.3.4. REST OF EUROPE 25
9.3.3.4.1. RUSSIA MARKET ESTIMATES AND FORECAST2012-2022($BILLION) 25
9.3.3.4.2. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 25
9.4. ASIA PACIFIC 25
9.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 25
9.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
9.4.3.1. CHINA 25
9.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
9.4.3.2. INDIA 25
9.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
9.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 26
9.4.3.3. JAPAN 26
9.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
9.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 26
9.4.3.4. AUSTRALIA 26
9.4.3.4.1. AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
9.4.3.4.2. AUSTRALIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 26
9.4.3.5. NEW ZEALAND 26
9.4.3.5.1. NEW ZEALAND MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
9.4.3.5.2. NEW ZEALAND MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 26
9.4.3.6. OTHERS 26
9.4.3.6.1. OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($BILLION) 27
9.4.3.6.2. OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 27
9.5. REST OF THE WORLD 27
9.5.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
9.5.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 27
9.5.3. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
9.5.4. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 27
9.5.5. SOUTH AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
9.5.6. SOUTH AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 27


CHAP 10. COMPETITIVE LANDSCAPE 28
10.1. ABBOTT LABORATORIES 29
10.1.1. COMPANY OVERVIEW 29
10.1.2. SCOT ANALYSIS 29
10.1.3. PRODUCT BENCHMARKING 29
10.1.4. STRATEGIC INITIATIVES 29
10.2. AUREON LABORATORIES 29
10.2.1. COMPANY OVERVIEW 29
10.2.2. SCOT ANALYSIS 29
10.2.3. PRODUCT BENCHMARKING 29
10.2.4. STRATEGIC INITIATIVES 29
10.3. AUTOGENOMICS 29
10.3.1. COMPANY OVERVIEW 29
10.3.2. SCOT ANALYSIS 29
10.3.3. PRODUCT BENCHMARKING 29
10.3.4. STRATEGIC INITIATIVES 29
10.4. BAYER HEALTHCARE 29
10.4.1. COMPANY OVERVIEW 29
10.4.2. SCOT ANALYSIS 29
10.4.3. PRODUCT BENCHMARKING 29
10.4.4. STRATEGIC INITIATIVES 29
10.5. BECTION DICKINSON 29
10.5.1. COMPANY OVERVIEW 29
10.5.2. SCOT ANALYSIS 29
10.5.3. PRODUCT BENCHMARKING 29
10.5.4. STRATEGIC INITIATIVES 29
10.6. CEPHEID 29
10.6.1. COMPANY OVERVIEW 29
10.6.2. SCOT ANALYSIS 30
10.6.3. PRODUCT BENCHMARKING 30
10.6.4. STRATEGIC INITIATIVES 30
10.7. DAKO 30
10.7.1. COMPANY OVERVIEW 30
10.7.2. SCOT ANALYSIS 30
10.7.3. PRODUCT BENCHMARKING 30
10.7.4. STRATEGIC INITIATIVES 30
10.8. DANAHER CORPORATION 30
10.8.1. COMPANY OVERVIEW 30
10.8.2. SCOT ANALYSIS 30
10.8.3. PRODUCT BENCHMARKING 30
10.8.4. STRATEGIC INITIATIVES 30
10.9. GEN PROBE (HOLOGIC) 30
10.9.1. COMPANY OVERVIEW 30
10.9.2. SCOT ANALYSIS 30
10.9.3. PRODUCT BENCHMARKING 30
10.9.4. STRATEGIC INITIATIVES 30
10.10. GENOMIC HEALTH INC. 30
10.10.1. COMPANY OVERVIEW 30
10.10.2. SCOT ANALYSIS 30
10.10.3. PRODUCT BENCHMARKING 30
10.10.4. STRATEGIC INITIATIVES 30
10.11. QIAGEN N.V. 30
10.11.1. COMPANY OVERVIEW 30
10.11.2. SCOT ANALYSIS 30
10.11.3. PRODUCT BENCHMARKING 30
10.11.4. STRATEGIC INITIATIVES 30
10.12. SIEMENS HEALTHCARE 31
10.12.1. COMPANY OVERVIEW 31
10.12.2. SCOT ANALYSIS 31
10.12.3. PRODUCT BENCHMARKING 31
10.12.4. STRATEGIC INITIATIVES 31
10.13. SYSMEX CORPORATION 31
10.13.1. COMPANY OVERVIEW 31
10.13.2. SCOT ANALYSIS 31
10.13.3. PRODUCT BENCHMARKING 31
10.13.4. STRATEGIC INITIATIVES 31
10.14. SKYLINE DIAGNOSTICS B.V. 31
10.14.1. COMPANY OVERVIEW 31
10.14.2. SCOT ANALYSIS 31
10.14.3. PRODUCT BENCHMARKING 31
10.14.4. STRATEGIC INITIATIVES 31
10.15. TRIMGEN CORPORATION 31
10.15.1. COMPANY OVERVIEW 31
10.15.2. SCOT ANALYSIS 31
10.15.3. PRODUCT BENCHMARKING 31
10.15.4. STRATEGIC INITIATIVES 31

TABLE 1 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY TYPE 2012-2022 ($ BILLION) 31
TABLE 2 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BYBREAST CANCER 2012-2022 ($ BILLION) 31
TABLE 3 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY PROSTATE CANCER 2012-2022 ($ BILLION) 31
TABLE 4 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY COLORECTAL CANCER2012-2022 ($ BILLION) 32
TABLE 5 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY CERVICAL CANCER 2012-2022 ($ BILLION) 32
TABLE 6 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY LIVER CANCER 2012-2022 ($ BILLION) 32
TABLE 7 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY LUNG CANCER 2012-2022 ($ BILLION) 32
TABLE 8 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY BLOOD CANCER 2012-2022 ($ BILLION) 32
TABLE 9 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY KIDNEY CANCER 2012-2022 ($ BILLION) 32
TABLE 10 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY OTHER CANCER 2012-2022 ($ BILLION) 32
TABLE 11 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY PRODUCT 2012-2022 ($ BILLION) 32
TABLE 12 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY INSTRUMENTS 2012-2022 ($ BILLION) 32
TABLE 13 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY REAGENTS 2012-2022 ($ BILLION) 32
TABLE 14 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY OTHERS 2012-2022 ($ BILLION) 32
TABLE 15 32
TABLE 16 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY TEST LOCATION 2012-2022 ($ BILLION) 32
TABLE 17 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY CLINICS AND OTHER ESTABLISHMENTS 2012-2022 ($ BILLION) 32
TABLE 18 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY POINT OF CARE 2012-2022 ($ BILLION) 32
TABLE 19 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2012-2022 ($ BILLION) 32
TABLE 20 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY PCR 2012-2022 ($ BILLION) 32
TABLE 21 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY MULTIPLEX 2012-2022 ($ BILLION) 32
TABLE 22 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY MULTIPLEX PCR 2012-2022 ($ BILLION) 33
TABLE 23 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY OTHERS 2012-2022 ($ BILLION) 33
TABLE 24 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY TRANSCRIPTION MEDIATED AMPLIFICATION 2012-2022 ($ BILLION) 33
TABLE 25 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY SITU HYBRIDIZATION2012-2022 ($ BILLION) 33
TABLE 26 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY SEQUENCING 2012-2022 ($ BILLION) 33
TABLE 27 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 2012-2022 ($ BILLION) 33
TABLE 28 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY CHIPS AND MICROARRAYS 2012-2022 ($ BILLION) 33
TABLE 29 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY MASS SPECTROMETRY 2012-2022 ($ BILLION) 33
TABLE 30 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY OTHERS TECHNOLOGIES 2012-2022 ($ BILLION) 33
TABLE 31 GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET BY REGION 2012-2022 ($ BILLION) 33
TABLE 32 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 33 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 33
TABLE 34 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 35 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 36 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 37 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 38 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 39 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 40 MEXICO MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 41 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 42 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 34
TABLE 43 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 44 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 45 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 46 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 47 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 48 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 49 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 50 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 51 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 52 ITALY MARKET ESTIMATES AND FORECAST2012-2022($BILLION) 34
TABLE 53 ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 54 OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 34
TABLE 55 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 56 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 35
TABLE 57 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 58 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 59 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 60 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 61 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 62 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 63 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 35
TABLE 64 AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 65 AUSTRALIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 35
TABLE 66 NEW ZEALAND MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 67 NEW ZEALAND MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 35
TABLE 68 35
TABLE 69 OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($BILLION) 35
TABLE 70 OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 35
TABLE 71 REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 72 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 73 SOUTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35

FIGURE 1 MARKET SHARE BY REGIONS 36
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 4 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 5 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 6 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 7 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 8 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 9 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 10 ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 11 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 12 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 13 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 14 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 15 AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 16 NEW ZEALAND MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 17 REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 18 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 19 37
FIGURE 20 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 21 SOUTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)